Predictive Oncology Q1 net loss $4.2M on revenue $0.4M; cash $5.2M, EPS -$1.04

Axe Compute Inc.

Net loss of ~$4.2M, wider than $3.5M loss in Q1 2023; diluted EPS -$1.04 vs -$0.86.
Revenue $419,646, up 75% YoY from $239,895, driven by STREAMWAY system sales.
Cash $5.2M at March 31, 2024, down from $8.7M at Dec 31, 2023.
Abstract accepted at ASCO 2024 for ovarian cancer machine-learning survival model; collaboration with Fujifilm on endotoxin testing announced.
FluGen collaboration for intranasal flu vaccine under $6.2M DoD grant progressing.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Axe Compute Inc. reported the quarter ended March 31, 2024 results: revenue $419,646, net income net loss of approximately $4.2 million, EPS $(1.04).

Period: the quarter ended March 31, 2024
Revenue: $419,646
Net income: net loss of approximately $4.2 million
EPS: $(1.04)
Result: reported results

Exact text from the filing

share for the quarter ended March 31, 2024, was $(1.04), compared to $(0.86) for the quarter ended March 31, 2023. Q1 2024 Financial Results: The company recorded revenue of $419,646 for the first quarter of 2024, compared to $239,895 for the comparable period in 2023. Revenues for the quarter ended March 31, 2024, and March 31, 2023, were primarily derived

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Axe Compute Inc. filing history →

Source: SEC EDGAR

accession 0001171843-24-002893

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.